» Articles » PMID: 38360993

Shared and Distinct Mechanisms of UBA1 Inactivation Across Different Diseases

Abstract

Most cellular ubiquitin signaling is initiated by UBA1, which activates and transfers ubiquitin to tens of E2 enzymes. Clonally acquired UBA1 missense mutations cause an inflammatory-hematologic overlap disease called VEXAS (vacuoles, E1, X-linked, autoinflammatory, somatic) syndrome. Despite extensive clinical investigation into this lethal disease, little is known about the underlying molecular mechanisms. Here, by dissecting VEXAS-causing UBA1 mutations, we discovered that p.Met41 mutations alter cytoplasmic isoform expression, whereas other mutations reduce catalytic activity of nuclear and cytoplasmic isoforms by diverse mechanisms, including aberrant oxyester formation. Strikingly, non-p.Met41 mutations most prominently affect transthioesterification, revealing ubiquitin transfer to cytoplasmic E2 enzymes as a shared property of pathogenesis amongst different VEXAS syndrome genotypes. A similar E2 charging bottleneck exists in some lung cancer-associated UBA1 mutations, but not in spinal muscular atrophy-causing UBA1 mutations, which instead, render UBA1 thermolabile. Collectively, our results highlight the precision of conformational changes required for faithful ubiquitin transfer, define distinct and shared mechanisms of UBA1 inactivation in diverse diseases, and suggest that specific E1-E2 modules control different aspects of tissue differentiation and maintenance.

Citing Articles

VEXAS, Chediak-Higashi syndrome and Danon disease: myeloid cell endo-lysosomal pathway dysfunction as a common denominator?.

Savy C, Bourgoin M, Cluzeau T, Jacquel A, Robert G, Auberger P Cell Mol Biol Lett. 2025; 30(1):12.

PMID: 39865233 PMC: 11765923. DOI: 10.1186/s11658-025-00691-0.


VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management.

Costa A, Pilo F, Pettinau M, Piga M, Carboni P, Piras E Ann Hematol. 2025; 104(1):253-262.

PMID: 39820409 PMC: 11868253. DOI: 10.1007/s00277-025-06207-2.


A novel UBA1 gene mutation in a patient with infantile respiratory distress syndrome.

Miyata M, Kojima A, Kawai Y, Uchida H, Boda H, Ishihara N Hum Genome Var. 2025; 12(1):2.

PMID: 39762237 PMC: 11704066. DOI: 10.1038/s41439-024-00307-7.


Clinical and Genetic Profiles of 5q- and Non-5q-Spinal Muscular Atrophy Diseases in Pediatric Patients.

Nishio H, Niba E, Saito T, Okamoto K, Lee T, Takeshima Y Genes (Basel). 2024; 15(10).

PMID: 39457418 PMC: 11506990. DOI: 10.3390/genes15101294.


VEXAS without vacuoles: Linking genotype to phenotype.

Zhukovsky S, Rets A, Braaten T, Patel A EJHaem. 2024; 5(5):981-986.

PMID: 39415928 PMC: 11474288. DOI: 10.1002/jha2.1016.


References
1.
McGrath J, Jentsch S, Varshavsky A . UBA 1: an essential yeast gene encoding ubiquitin-activating enzyme. EMBO J. 1991; 10(1):227-36. PMC: 452634. DOI: 10.1002/j.1460-2075.1991.tb07940.x. View

2.
Stephen A, Trausch-Azar J, Ciechanover A, Schwartz A . Human ubiquitin-activating enzyme, E1. Indication of potential nuclear and cytoplasmic subpopulations using epitope-tagged cDNA constructs. J Biol Chem. 1994; 269(52):33171-8. View

3.
Farley-Barnes K, Ogawa L, Baserga S . Ribosomopathies: Old Concepts, New Controversies. Trends Genet. 2019; 35(10):754-767. PMC: 6852887. DOI: 10.1016/j.tig.2019.07.004. View

4.
Lv Z, Rickman K, Yuan L, Williams K, Selvam S, Woosley A . S. pombe Uba1-Ubc15 Structure Reveals a Novel Regulatory Mechanism of Ubiquitin E2 Activity. Mol Cell. 2017; 65(4):699-714.e6. PMC: 5319395. DOI: 10.1016/j.molcel.2017.01.008. View

5.
Wu Z, Gao S, Gao Q, Patel B, Groarke E, Feng X . Early activation of inflammatory pathways in UBA1-mutated hematopoietic stem and progenitor cells in VEXAS. Cell Rep Med. 2023; 4(8):101160. PMC: 10439277. DOI: 10.1016/j.xcrm.2023.101160. View